Noteworthy lectures focus on cutting edge therapeutics

Article

Oncology NEWS International guest editor Dr. Andrew D. Seidman recommends SABCS 2008 lectures on modern molecular science, molecular profiling, and the American Association of Cancer Research distinguished lectureship in breast cancer research.

SAN ANTONIO-Oncology NEWS International guest editor Dr. Andrew D. Seidman recommends the following SABCS 2008 lectures:

  • William L. McGuire memorial lecture What is cancer? How modern molecular science is challenging traditional views," given by Larry Norton, MD, Memorial Sloan-Kettering Cancer Center, New York



  • Mini-symposium "Molecular Profiling for guiding therapeutic decisions," moderated by Suzanne A.W. Fuqua, PhD, from Baylor College of Medicine, Houston, and Laura van't Veer, PhD, Netherlands Cancer Institute, Amsterdam. Topics: RNA, personalized medicine, predictors of response to adjuvant therapy.



  • American Association of Cancer Research (AACR) distinguished lectureship in breast cancer research Titled "Deconstructing metastasis," the lecture will be delivered by Joan Massagu, PhD, of Memorial Sloan-Kettering Cancer Center, New York

 

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.